NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Dasatinib

Last Revision: December 21, 2020.

Estimated reading time: 1 minute

CASRN: 302962-49-8

image 135143589 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

Although one breastfed infants apparently experienced no adverse effects during maternal use of dasatinib, no long-term data are available. Because dasatinib and its metabolite are more than 90% bound to plasma proteins, the amounts in milk are likely to be low. However, there is little published experience with dasatinib during breastfeeding, and an alternate drug may be preferred, especially while nursing a newborn or preterm infant. National Comprehensive Cancer Network guidelines recommend avoiding breastfeeding during dasatinib therapy and the manufacturer recommends withnholding breastfeeding until 2 weeks following the last dose.[1]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

A woman with chronic myeloid leukemia received dasatinib 100 mg daily throughout pregnancy and continuing postpartum, apparently while breastfeeding her infant (extent not stated). No adverse reactions were reported in her infant.[2]

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Imatinib

References

1.
Deininger MW, Shah NP, Altman JK, et al. Chronic myeloid leukemia, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:1385–415. [PubMed: 33022644]
2.
Alizadeh H, Jaafar H, Kajtar B. Outcome of 3 pregnancies in a patient with chronic myeloid leukemia who received 3 types of tyrosine kinase inhibitors each in different pregnancy: Follow-up of the case with a review of published reports. Ann Saudi Med. 2015;35:468–71. [PMC free article: PMC6074472] [PubMed: 26657232]

Substance Identification

Substance Name

Dasatinib

CAS Registry Number

302962-49-8

Drug Class

Breast Feeding

Lactation

Antineoplastic Agents

Enzyme Inhibitors

Protein Kinase Inhibitors

Signal Transduction Inhibitors

Tyrosine Kinase Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

Similar articles in PubMed

  • Review Nilotinib[Drugs and Lactation Database (...]
    Review Nilotinib
    . Drugs and Lactation Database (LactMed). 2006
  • Review Bosutinib[Drugs and Lactation Database (...]
    Review Bosutinib
    . Drugs and Lactation Database (LactMed). 2006
  • Review Ponatinib[Drugs and Lactation Database (...]
    Review Ponatinib
    . Drugs and Lactation Database (LactMed). 2006
  • Review Imatinib[Drugs and Lactation Database (...]
    Review Imatinib
    . Drugs and Lactation Database (LactMed). 2006
  • Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats.[Drug Metab Dispos. 2008]
    Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats.
    He K, Lago MW, Iyer RA, Shyu WC, Humphreys WG, Christopher LJ. Drug Metab Dispos. 2008 Dec; 36(12):2564-70. Epub 2008 Sep 11.
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...